Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease.
BACKGROUND
Bronchodilators are used to treat bronchial hyper-responsiveness in asthma. Bronchial hyper-responsiveness may be a component of acute chest syndrome in people with sickle cell disease. Therefore, bronchodilators may be useful in the treatment of acute chest syndrome. This is an update of a previously published Cochrane Review.


OBJECTIVE
To assess the benefits and risks associated with the use of bronchodilators in people with acute chest syndrome.


METHODS
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. Additional searches were carried out on MEDLINE (1966 to 2002) and Embase (1981 to 2002).Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 11 July 2016.


METHODS
Randomised or quasi-randomised controlled trials. Trials using quasi-randomisation methods will be included in future updates of this review if there is sufficient evidence that the treatment and control groups are similar at baseline.


METHODS
We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease.


RESULTS
We found no trials investigating the use of bronchodilators for acute chest syndrome in people with sickle cell disease.


CONCLUSIONS
If bronchial hyper-responsiveness is an important component of some episodes of acute chest syndrome in people with sickle cell disease, the use of inhaled bronchodilators may be indicated. There is need for a well-designed, adequately-powered randomised controlled trial to assess the benefits and risks of the addition of inhaled bronchodilators to established therapies for acute chest syndrome in people with sickle cell disease.
Sickle Cell Unit, Tropical Medicine Research Institute, University of the West Indies, Mona, Kingston 7, Jamaica.
Jennifer M
JM
Knight-Madden
Ian R
IR
Hambleton
Pediatr Pulmonol. 1999 Sep;28(3):205-16
10495338
N Engl J Med. 2000 Jun 22;342(25):1855-65
10861320
J Pediatr. 2001 Feb;138(2):188-92
11174615
Lancet. 2001 Mar 3;357(9257):680-3
11247552
Bull World Health Organ. 2001;79(8):704-12
11545326
Int J Epidemiol. 2002 Feb;31(1):140-9
11914310
Cochrane Database Syst Rev. 2003;(3):CD003733
12917983
BMJ. 2003 Sep 6;327(7414):557-60
12958120
Pediatr Emerg Care. 2005 Feb;21(2):99-101
15699818
Thorax. 2005 Mar;60(3):206-10
15741436
Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006957
18254121
Am J Dis Child. 1991 Jun;145(6):603-4
2035485
J Clin Pathol. 1991 Jun;44(6):459-63
2066423
Cochrane Database Syst Rev. 2012 Jul 11;(7):CD003733
22786487
Cochrane Database Syst Rev. 2014 Aug 02;(8):CD003733
25086371
Ann Allergy. 1988 Aug;61(2):129-32
3400898
East Afr Med J. 1970 Aug;47(8):434-9
5479792
Br Med J (Clin Res Ed). 1982 Aug 28-Sep 4;285(6342):633-5
6819042
Ann Allergy. 1983 May;50(5):320-2
6846922
Blood. 1994 Jul 15;84(2):643-9
7517723
Blood. 1995 Jul 15;86(2):776-83
7606007
N Engl J Med. 1994 Jun 9;330(23):1639-44
7993409
Med Hypotheses. 1997 Jan;48(1):11-7
9049983
J Pediatr. 1997 Aug;131(2):278-83
9290616